ORKA
ORKA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$1.41M
Insider Sales
46
$343.71M
Total Volume
$345.12M
76 transactions
Net Activity
$342.30M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •High accumulation: total purchase value exceeds $1M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale+OE Insiders
$509.77B total
Fairmount Funds Management LLC
Dir, 10%
$300.01M total
Klein Lawrence Otto
CEO
$11.79M total
Dambkowski Carl
Dir
$8.65M total
Quinlan Paul T
GC
$7.47M total
Quick Actions
ORKA has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. ORKA ranks #178 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at ORKA (ORKA) engaged in a total of 76 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 46 were sales. The total volume of insider trading reached $345.12M.
The net insider activity for ORKA shows a net selling bias of $342.30M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 4.15M shares valued at $509.77B on Feb 10, 2025.
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
ORKA - Oruka Therapeutics Inc Stock Price and Quote
Jefferies reiterates Buy on Oruka Therapeutics stock ahead of data
In a psoriasis trial, 71% had clear skin six months after their last dose
What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders
Fund Update: New $6.5M $ORKA stock position opened by Fisher Asset Management, LLC
FAQs About ORKA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ORKA.